Megan Clowse
Rheumatology · Durham, NCNPI 1063595213
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $66,278 of the $71,719 with a category attached, or 92.4%. UCB SA accounts for 68.4% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $21,213 and has fallen 98.9% since, to $235 in 2025. Among rheumatology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $2390.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$49K
- UCB, Inc.$8K
- Lilly USA, LLC$6K
- E.r. Squibb & Sons, L.L.C.$4K
- GSK$4K
- Amgen$580
- plus $262 from 3 others
Across 43 payments — averaging $25,266 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$511K
- UCB SA$345K
- Pfizer$225K
- UCB, Inc.$6K
What the payments were for
- Consulting fees$66,27892%
- Speaking & faculty fees$4,2396%
- Travel & lodging$8391%
- Food & beverage$3621%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 13 | $49,053 |
| UCB, Inc. | 8 | $8,304 |
| Lilly USA, LLC | 1 | $5,600 |
| E.r. Squibb & Sons, L.L.C. | 1 | $4,239 |
| GSK | 1 | $3,680 |
| Amgen | 1 | $580 |
| AstraZeneca | 3 | $207 |
| Janssen Research & Development, LLC | 1 | $27 |
| Aurinia Pharma U.S., Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$71,719 in reported general payments places this provider in the 90th percentile of 210 rheumatology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 35 | $1,620 |
| MethotrexateMethotrexate Sodium | 22 | $600 |
| Prednisone | 30 | $318 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Durham
- Ralph SnydermanDurham$1.3M
- Joseph ShanahanDurham$407K
- Virginia KrausDurham$31K
- Laura SchanbergDurham$20K
- David LeverenzDurham$11K
- Gordon LamCharlotte$2.7M
- Wendy SimmonsWilmington$462K
- Andrew LasterCharlotte$421K
- Ana RossRaleigh$417K
- Gwenesta MeltonFayetteville$410K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.